Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and other members of Enanta management will participate in the following three investor conferences during the month of September:
- Wednesday, September 3, 2014, the FBR & Company Inaugural Healthcare Conference in Boston. There is no webcast presentation.
- Thursday, September 4, 2014, at 2:00 p.m. ET, Enanta management will present a corporate overview during the Baird 2014 Healthcare Conference in New York.
- Monday, September 8, 2014 at 2:00 p.m. ET, Enanta management will present a corporate overview during the Morgan Stanley 2014 Global Healthcare Conference in New York.
Live webcasts and replays of the Baird 2014 Healthcare conference and the Morgan Stanley 2014 Global Healthcare conference presentations can be accessed by visiting the “Calendar of Events” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of each webcast will be available following the presentation and will be archived for approximately 30 days.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.
Sorry. No data so far.